Association of serum prostate-specific antigen with Complete Blood Counts in patients with prostatic cancer

Background: Prostate cancer is the second most common cancer and one of the most leadingcauses of death in men worldwide. The prostate-specific antigen (PSA) as a screening methodshowed that there has been a slight decrease in prostate cancer mortality. Effective biomarkers inscreening and diagnosis would be beneficial for avoiding unnecessary operations. The predictive andprognostic value of complete blood count (CBC) has been manifested by recent studies. We aimed todetermine the association of serum PSA with Complete blood counts in patients with prostate cancer.Method: The present study included 100 subjects, 50 patients diagnosed with new prostate cancerand 50 patients with prostate cancer. All the was undertaken in the central diagnostic laboratory atVIMS and RC. Blood samples were collected from all the subjects after taken permission from theinstitutional ethics committee and consent form. The haemoglobin, RBCs, MCV, MCHC, RDW will beanalysed by using laboratory standard methods (Beckman coulter LH-780) and The serum PSAlevels are estimated by commercially available kits based on enzyme-linked immunosorbent assay(ELISA). Results: In the present study found significantly elevated levels of a prostate specificantigen in both groups of prostatic cancer patients. The reduced levels of hemoglobin, red bloodcells, platelets, neutrophils were observed in prostatic cancer patients when compared to newlydiagnosed prostate cancer patients. The PSA levels were negatively correlated with total bloodcounts. Conclusion: This study suggests that the elevated levels of prostate specific antigen wereuseful for diagnosis and prognosis of prostatic cancers, along with the monitoring of complete bloodcount may be useful for the treatment of patients with prostatic cancers.

Download Full-text

Nadir Prostate-Specific Antigen After Neoadjuvant Androgen Suppression (AS) in Prostate Cancer Patients Receiving Short-term AS and Radiation Therapy: Pooled Analysis of Four NRG Oncology/RTOG Randomized Clinical Trials

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2015.07.111 ◽

2015 ◽

Vol 93 (3) ◽

pp. S46

Author(s):

C.L. Hallemeier ◽

P. Zhang ◽

T.M. Pisansky ◽

G.E. Hanks ◽

D.G. McGowan ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Radiation Therapy ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Randomized Clinical Trials ◽

Specific Antigen ◽

Pooled Analysis ◽

Short Term ◽

Androgen Suppression

Download Full-text

Detection of N,N-diacetyllactosamine (LacdiNAc) containing free prostate-specific antigen for early stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients

Bioorganic & Medicinal Chemistry ◽

10.1016/j.bmc.2021.116156 ◽

2021 ◽

Vol 39 ◽

pp. 116156

Author(s):

Aniko Bertokova ◽

Tomas Bertok ◽

Eduard Jane ◽

Michal Hires ◽

Petra Ďubjaková ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Early Stage ◽

Specific Antigen ◽

Cancer Diagnostics ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Prostate-Specific Antigen: From Promising to Disappointment Tool for Diagnosis of Chronic Renal Failure in Predialysis Patients

Asian Journal of Oncology ◽

10.1055/s-0041-1729346 ◽

2021 ◽

Vol 07 (02) ◽

pp. 082-084

Author(s):

Ali Abdul Hussein S Al-Janabi

Keyword(s):

Prostate Cancer ◽

Renal Failure ◽

Chronic Renal Failure ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Enzyme Linked Immunosorbent Assay ◽

Elderly Men ◽

A Value ◽

Total Psa ◽

Moderate Elevation

Abstract Introduction Prostate-specific antigen (PSA) is a biomarker commonly used for detection of prostate cancer. Its viability as a marker for diagnosis of chronic renal failure (CRF) in predialysis patients was investigated. Methods Sera from 230 patients with CRF were analyzed by enzyme-linked immunosorbent assay (ELISA) for determining total PSA (tPSA) levels before hemodialysis. Results Of the patients investigated, 98.69% had a normal PSA level with a value less than 4 ng/mL. Three elderly men with both kidney failure showed a moderate elevation of PSA level. Conclusion PSA is considered a nonsignificant indicator for diagnosis of CRF.

Download Full-text

Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels

Prostate Cancer and Prostatic Diseases ◽

10.1038/sj.pcan.4500957 ◽

2007 ◽

Vol 10 (3) ◽

pp. 274-278 ◽

Cited By ~ 14

Author(s):

N Tanaka ◽

K Fujimoto ◽

Y Chihara ◽

M Torimoto ◽

Y Hirao ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Prostatic Volume ◽

Predictive Parameters

Download Full-text

Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients

The Prostate ◽

10.1002/pros.1064 ◽

2001 ◽

Vol 47 (3) ◽

pp. 205-211 ◽

Cited By ~ 21

Author(s):

Alfredo Berruti ◽

Luigi Dogliotti ◽

Alessandra Mosca ◽

Roberto Tarabuzzi ◽

Mirella Torta ◽

...

Keyword(s):

Prostate Cancer ◽

Growth Factor ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Chromogranin A ◽

Advanced Prostate Cancer ◽

Specific Antigen ◽

Somatostatin Analog ◽

Insulin Like Growth Factor ◽

Circulating Levels

Download Full-text

Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm-2013-0675 ◽

2014 ◽

Vol 52 (5) ◽

Cited By ~ 64

Author(s):

Giorgio Treglia ◽

Luca Ceriani ◽

Ramin Sadeghi ◽

Giampiero Giovacchini ◽

Luca Giovanella

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Detection Rate ◽

Meta Analysis ◽

Specific Antigen ◽

Choline Pet ◽

Pet Ct

Download Full-text

Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level

Asia-Pacific Journal of Clinical Oncology ◽

10.1111/ajco.12313 ◽

2014 ◽

Vol 13 (2) ◽

pp. e65-e71 ◽

Cited By ~ 2

Author(s):

Jeremy Yuen Chun Teoh ◽

James Hok Leung Tsu ◽

Steffi Kar Kei Yuen ◽

Samson Yun Sang Chan ◽

Peter Ka Fung Chiu ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Androgen Deprivation Therapy ◽

Metastatic Prostate Cancer ◽

Specific Antigen ◽

Androgen Deprivation ◽

Survival Outcomes ◽

Primary Androgen Deprivation Therapy ◽

Primary Androgen Deprivation

Download Full-text

Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target

Current Urology ◽

10.1159/000447225 ◽

2018 ◽

Vol 12 (1) ◽

pp. 13-19 ◽

Cited By ~ 1

Author(s):

Athanasios Skarmoutsos ◽

Ioannis Skarmoutsos ◽

Ioannis Katafigiotis ◽

Elisavet Tataki ◽

Athina Giagini ◽

...

Keyword(s):

Prostate Cancer ◽

Growth Factor ◽

Early Diagnosis ◽

Prostate Specific Antigen ◽

Characteristic Curve ◽

Specific Antigen ◽

Predictive Ability ◽

Platelet Derived Growth Factor ◽

Enzyme Linked Immunosorbent Assay ◽

Transrectal Biopsy

Introduction: Although the prostate specific antigen revolutionized the diagnosis of prostate cancer (PCa), it has its limitations. We prospectively examined the potential use of the platelet-derived growth factor-BB (PDGF-BB) as a urine biomarker for the early diagnosis of PCa. Materials and Methods: The urine samples of 118 patients were collected after a prostatic massage and all the patients subsequently underwent ultrasound-guided transrectal biopsy. PDGF-BB was detected in the urine by enzyme-linked immunosorbent assay. Results: Patients with PCa had greater levels of prostate specific antigen and PDGF-BB. Receiver operating characteristic curve analysis showed that the optimal cut-of of PDGF-BB for the prediction of PCa was 1,504.9 with a sensitivity of 60% and a specificity of 51.3%. For a 100 unit increase in PDGF-BB, the likelihood for PCa increased about 4%. Conclusion: PDGF-BB showed a significant predictive ability for PCa. Detection of PDGF-BB in urine with Elisa was easy and improved our diagnostic accuracy in the diagnosis of PCa.

Download Full-text